Cargando…
Therapy of Type 2 diabetes: more gliflozines and less metformin?
Metformin is a frequently used anti-diabetic drug. In addition to the well-known modulating properties on glyco-metabolic control, metformin reduces cardiovascular (CV) risk partly independently of its anti-hyperglycaemic effect. The use of ‘new’ anti-diabetic drugs, inhibitors of the renal Na-gluco...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120941/ https://www.ncbi.nlm.nih.gov/pubmed/37091638 http://dx.doi.org/10.1093/eurheartjsupp/suad098 |